Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

451
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
451
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

406
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
406
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

234
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
234
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

235
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
235
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

352
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
352

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global O-GlcNAcome Identifies O-GlcNAcylated Proteins Regulating Oligodendrocyte Precursor Cells Differentiation.

Acta biochimica et biophysica Sinica·2026
Same author

Sports tourism motivation and tourist satisfaction in resort Ski tourism: A distal mediation model of tourist expectation and experience quality.

PloS one·2026
Same author

Decreasing Microtubule Detyrosination Improves Cardiac Mechanics and Sodium Channel Function in Arrhythmogenic Cardiomyopathy.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Genome-Wide Identification and Characterization of NAC Transcription Factors in Avocado (<i>Persea americana</i>): Expression Analysis During Fruit Development.

Genes·2026
Same author

High-Value Utilization of Coconut Kernel Fiber By-Products: The Insulin-Sensitizing Effect of Novel α-Glucosidase-Inhibiting Peptides Derived from Coconut Kernel Fiber on T2DM Mice.

Foods (Basel, Switzerland)·2026
Same author

Preparation methods, structural characterization, pharmacological properties, and potential industrial utilization of polysaccharides from Aloe vera: A review.

International journal of biological macromolecules·2026

Related Experiment Video

Updated: Mar 6, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Patient Preference for Dosing Frequency Based on Prior Biologic Experience.

Mingliang Zhang, Chureen Carter, William H Olson

    Journal of Drugs in Dermatology : JDD
    |March 17, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Patients with moderate-to-severe plaque psoriasis prefer less frequent biologic dosing. The least frequent dosing option (once every 12 weeks) was favored by most patients, influencing treatment decisions.

    More Related Videos

    Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
    06:13

    Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

    Published on: February 21, 2020

    7.1K
    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
    08:38

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

    Published on: November 8, 2015

    17.5K

    Related Experiment Videos

    Last Updated: Mar 6, 2026

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    10.7K
    Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
    06:13

    Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

    Published on: February 21, 2020

    7.1K
    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
    08:38

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

    Published on: November 8, 2015

    17.5K

    Area of Science:

    • Dermatology
    • Pharmacology
    • Patient-Reported Outcomes

    Background:

    • Limited research exists on patient preferences for biologic dosing frequency in psoriasis.
    • Understanding patient preferences is crucial for optimizing treatment adherence and satisfaction.

    Purpose of the Study:

    • To investigate patient preferences for dosing frequency of biologic treatments for moderate-to-severe plaque psoriasis.
    • To explore how prior biologic experience influences these preferences.

    Main Methods:

    • A survey was administered to patients with plaque psoriasis identified from a healthcare claims database.
    • Preferences for dosing intervals (weekly, bi-weekly, monthly, or longer) were assessed.
    • Data were analyzed based on biologic-naïve status and experience with specific biologics (etanercept, adalimumab, ustekinumab).

    Main Results:

    • A majority of both biologic-naïve (68.8%) and biologic-experienced (69.4%) patients favored the least frequent dosing option (once every 12 weeks).
    • Patients with any experience with ustekinumab preferred a dosing interval of every 2-3 months, irrespective of other biologic experience.
    • Patients without ustekinumab experience were more inclined towards 1-2 week dosing intervals.

    Conclusions:

    • The least frequent dosing intervals are preferred by biologic-naïve patients and those with ustekinumab experience.
    • Dosing frequency is a significant factor in shared decision-making for biologic psoriasis treatments.